Eli Lilly and Company reports that the US Food and Drug Administration (FDA) has approved Cyramza (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. Cyramza now has two approvals for this indication. In April 2014, the US FDA approved Cyramza as a single agent for patients in this setting.

Cyramza was granted orphan drug designation by the FDA for this indication. In the US, orphan drug status is given by the Office of Orphan Products Development to medicines that show promise for the treatment of rare diseases.

Source: Eli Lilly and Company